Business
Completion of CAP accreditation audit
Verici Dx Plc has successfully completed its second biennial inspection by the College of American Pathologists (CAP) for its clinical laboratory, passing with no deficiencies. This accreditation is crucial for maintaining high standards in clinical laboratory practice and ensuring the reliability of test results for organ transplant diagnostics, which directly supports the company's commitment to patient health and its role as a trusted partner to clinicians. Disclaimer*
About this update from Verici Dx Plc
Verici Dx plc (" Verici Dx " or the " Company ") Completion of CAP accreditation audit Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has successfully completed its second biennial inspection of the Company's clinical laboratory, accredited by the College of American Pathologists ("CAP"). CAP is one of the leading US organisations for reviewing clinical laboratories and maintaining this accreditation is an essential part in continuing to implement the highest standards in clinical laboratory practice. The inspection passed with no deficiencies, showing Verici Dx's commitment to compliance and maintaining excellence in daily clinical laboratory operations according to CAP requirements and their respective annual updates. By continuing to follow these strict CAP guidelines and pass CAP accreditation audits, Verici Dx can consistently provide reliable test results under its quality management system and further improve patient health. Dave Schultenover, VP Quality and Regulatory Affairs at Verici Dx, said: "Verici Dx values the clinicians and patients that put their trust in our clinical laboratory, enabling a level of personalised care that has not been available to kidney transplant patients until now. We are dedicated to continuing to meet or exceed the regulatory requirements to be a trusted partner to clinicians." Verici Dx plc www.vericidx.com Sara Barrington, CEO Via Walbrook PR Singer Capital Markets (Nominated adviser, Joint Broker) Tel: +44 (0)20 7496 3000 Phil Davies / Sam Butcher Oberon Capital (Joint Broker) Tel: +44 (0)20 3179 0500 Mike Seabrook / Adam Pollock Walbrook PR (Media & Investor Relations) Tel: +44 (0)20 7933 8780 or [email protected] Alice Woodings / Paul McManus Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893